Finally, a Vaccine for Cancer

The New York Times
Original Story by The New York Times
November 16, 2026
Finally, a Vaccine for Cancer

An experimental cancer vaccine targeting melanoma has shown that patients who receive it after tumor removal experience a meaningful drop in recurrence and mortality risk, marking the first-of-its-kind approach that could transform cancer treatment. The breakthrough, developed by Merck and Moderna, builds on a long-standing idea and could redefine post-surgical care for melanoma. While early results signal strong potential, the path forward includes broader trials to confirm durability and explore applicability to other cancers. The development injects fresh momentum into cancer immunotherapy, with researchers and patients watching closely for long-term outcomes and next steps.

Dive Deeper:

  • Trial results for the melanoma vaccine indicate that post-surgical patients who received the vaccine were 42 percent less likely to experience cancer recurrence or death within two years, compared with a control group. The finding positions the vaccine as a potentially paradigm-shifting adjuvant therapy.

  • The vaccine is being developed by Merck and Moderna, marking a collaboration between two major biopharma players in a pioneering cancer-immunotherapy approach. The study focuses on patients who had tumors surgically removed, selecting a high-risk population for recurrence.

  • Experts describe this as a first-of-its-kind vaccine that moves beyond prevention to active treatment in cancer, reviving a century-old concept with modern biotechnology. The result has generated renewed optimism among clinicians and patients about vaccine-based strategies.

  • Researchers emphasize that while the early data are promising, further trials are needed to validate durability, assess broader applicability to other cancer types, and determine long-term safety and effectiveness. The next phase will likely expand participant diversity and follow patients over longer periods.

  • The coverage ties the findings to ongoing discussions about immunotherapy and cancer vaccines, highlighting the potential shift in standard care for melanoma and signaling possible new avenues for research and development in oncology.

Latest News

Related Stories